Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

This study is testing a combination of two drugs — dostarlimab (an immunotherapy checkpoint inhibitor) and niraparib (a PARP inhibitor) — in men with advanced or metastatic penile cancer that has come back or progressed after prior treatment. **You may be eligible if...** - You are a man with confirmed stage III (unresectable) or stage IV penile cancer - Your cancer has progressed after or you could not tolerate up to one prior line of therapy - You have measurable disease on imaging - Your life expectancy is more than 12 weeks - You are in good functional health (ECOG 0–1, or possibly 2 with investigator approval) **You may NOT be eligible if...** - You have previously received immunotherapy (checkpoint inhibitors like anti-PD-1 or anti-CTLA-4 drugs) - Your cancer has spread to the brain and is active/untreated - You have significant side effects remaining from prior treatment - Your organ function is not adequate Talk to your doctor to see if this trial is right for you.